CCM
LKFT

CAAS Capital Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

CAAS Capital Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-32,869
Closed -$2.26M – 1018
2021
Q2 		$2.26M Buy
+32,869
New +$2.51M 0.04% 375

Other funds holding LKFT

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

CAAS Capital Management's LKFT Position: Q3 2021 in Review

CAAS Capital Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2021, closing a stake of 32,869 shares — an estimated $2.26M sold.

CAAS Capital Management first reported a position in LKFT in Q2 2021 and held it in 1 quarter. The position peaked at $2.26M in Q2 2021. 81 funds tracked by Wall St. Rank hold LKFT as of Q3 2021.

  • CAAS Capital Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2021 after selling out during the quarter.
  • CAAS Capital Management sold 32,869 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2021, an estimated $2.26M.
  • CAAS Capital Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2021 and held it in 1 quarter.
  • CAAS Capital Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $2.26M in Q2 2021.
  • 81 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2021.

Based on CAAS Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.